Ask AI
ProCE Banner Activity

Precision Medicine in Metastatic Castration–Resistant Prostate Cancer: Leveraging PARP Inhibitors for Optimal Outcomes

Clinical Thought

This expert commentary discusses the medical need and rationale for using PARP inhibitor–based treatment in patients with metastatic castration–resistant prostate cancer, including best practices in testing to inform treatment selection, recent guideline updates, and enhancing communication.

Released: July 15, 2025

Expiration: January 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson and Pfizer Inc.

Johnson & Johnson

Pfizer, Inc.

Faculty Disclosure

Primary Author

Neeraj Agarwal, MD, FASCO, has no relevant financial relationships to disclose.

Karim Fizazi, MD, PhD: consultant/advisor/speaker: Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Clovis, CureVac, Daiichi Sankyo, Janssen, MacroGenics, Merck Sharp & Dohme, Novartis/Advanced Accelerator Applications, Orion, Pfizer, Sanofi.

Rana R. McKay, MD, FASCO: consultant/advisor/speakers: Ambrx, Arcus, Artera, AI, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostic, Boundless Bio, Bristol Myers Squibb, Calithera, Caris, Daiichi Sankyo, Dendreon, Exelixis, Johnson & Johnson, Lilly, Neomorph, Nimbus, Novartis, Oncternal, Pfizer, Precede, Sanofi, SeaGen, Sorrento Therapeutics, Sumitomo Pharma, Telix, Tempus.